Area of Focus
A concise overview of HIV biology and emerging AI-supported vaccine research. GAYAR does not currently present a dedicated HIV research project or confirmed HIV-specific research scope.
01 · Understanding the area
HIV combines a multi-step replication cycle with extensive genetic and antigenic variation. Understanding that molecular cycle is central to treatment, while vaccine research increasingly uses computational and AI-assisted methods to navigate large sequence, structure, and immune-response datasets.
Human immunodeficiency virus (HIV) attacks the immune system by infecting CD4 T cells. Without effective treatment, progressive loss of these cells can weaken immune defenses and lead to acquired immunodeficiency syndrome (AIDS). Antiretroviral therapy can suppress viral replication and allow people with HIV to live long, healthy lives.
HIV binds to and enters CD4 cells, converts its RNA into DNA through reverse transcription, integrates that viral DNA into the host-cell genome, and then uses the cell to produce and assemble new virus particles. Antiretroviral drug classes interrupt different stages of this life cycle, including entry, reverse transcription, integration, and maturation.
AI can help researchers analyze large viral and immune datasets, prioritize candidate immunogens, study antibody–antigen interactions, and accelerate parts of vaccine-development workflows. The Gates Foundation is funding AI adoption in vaccine research, including work with IAVI, but no HIV vaccine is currently approved; computational predictions still require laboratory and clinical validation.
Distribution map
This map shows the estimated share of people aged 15–49 living with HIV in 2024. It uses UNAIDS epidemic estimates processed for visualization by Our World in Data and should be read as an age-specific prevalence measure, not the share of the total population.
